pharma · Moderate to severe systemic lupus erythematosus · Lupus Erythematosus, Systemic
Viatris Pharmaceuticals Co
Viatris Pharmaceuticals Co.,
Viatris Healthcare is a pharma organization headquartered in FR. Primary therapeutic focus areas include Moderate to severe systemic lupus erythematosus, Lupus Erythematosus, Systemic, Acute Myocardial Infarction, Stable
FR HQ
4 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- FR
- Employees
- 4
- Programs
- 8
- Drugs
- 23
- Patents
- 0
Selatogrel
Phase 2 · small molecule · Stable Coronary Artery Disease
Selatogrel for Stable Coronary Artery Disease is a Phase 2 program (small_molecule) at Viatris Pharmaceuticals Co., with 1 ClinicalTrials.gov record(s).
Internal code ID-076A201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Viatris Pharmaceuticals Co.,
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Stable Coronary Artery Disease
- Status
- completed
- Trials
- 1